US Patent 6,353,029: Claim Scope, Expiration, Orange Book Status, and Tretinoin Patent Landscape

US Patent 6,353,029 covers a stabilized topical tretinoin solution containing 4-hydroxyanisole, polyethylene glycol, antioxidants, a chelating agent, lower alkanol, water, and an acidic pH. The broadest claim requires the combined formulation architecture, including at least two antioxidant functions and at least 12% water. The narrower claims specify preferred concentration ranges and, in claim 13, a near-exact formulation.

The patent is an expired formulation patent. Its commercial significance is historical rather than exclusionary. It does not currently block generic tretinoin products, although its disclosure remains relevant to formulation design, prior-art analysis, patent validity assessments, and freedom-to-operate reviews.

What does US Patent 6,353,029 protect?

US 6,353,029 protects a chemically stabilized topical solution of tretinoin. The invention addresses degradation of tretinoin in liquid formulations, particularly formulations containing water and alcohol.

The central formulation requires:

Component	Claim 1 range
4-Hydroxyanisole, also called 4-methoxyphenol or HA	About 0.5% to 5% w/v
Tretinoin	About 0.002% to 0.05% w/v
Liquid low-molecular-weight PEG	About 2% to 10% v/v
Antioxidant or antioxidant mixture	About 0.001% to 1.5% w/v
Chelating agent	About 0.001% to 0.1% w/v
Lower alkanol	About 50% to 88% v/v
Water	Quantity sufficient to 100%; at least 12% v/v
pH	About 2.5 to 5

The claim is cumulative. A competing product must satisfy every limitation of claim 1 to create a literal infringement issue. A formulation containing tretinoin and ethanol alone would not fall within the claim.

The formulation also requires an antioxidant system selected to provide at least two of three stated functions:

Oxygen scavenging.
Free-radical chain termination.
Reduction.

This functional limitation is important. The claim is not directed to any antioxidant in any amount. The selected antioxidant or mixture must perform at least two specified stabilization roles.

How do the dependent claims narrow the patent scope?

Claims 2 through 13 narrow the formulation through concentration, ingredient, pH, water-content, and recipe limitations.

Claim	Principal limitation
2	Preferred concentration ranges for all major components
3	Narrower preferred formulation centered on 2% HA and 0.01% tretinoin
4	Closed list of permitted antioxidants
5	Closed list of permitted chelating agents
6	At least 15% water
7	At least 20% water
8	pH about 3 to 4.5
9	pH about 4
10	Antioxidant functions are oxygen scavenging and free-radical chain termination
11	PEG-8, specified antioxidants, ethanol or isopropanol, and citric acid or disodium EDTA
12	Addition of an acidulant to adjust pH
13	Specific quantitative formulation

Claim 13 is the most commercially concrete claim. It recites:

2% w/v 4-hydroxyanisole;
0.01% w/v tretinoin;
77.8% v/v ethyl alcohol USP;
3.9% v/v PEG-8;
0.088% w/v BHT;
0.044% w/v ascorbic acid;
0.0088% w/v citric acid;
0.0044% w/v ascorbyl palmitate;
0.0044% w/v disodium EDTA; and
18.5% water.

A product matching the claim 13 recipe would also fall within claim 1, assuming the stated pH and antioxidant-function limitations are satisfied.

What formulation elements create the principal infringement risk?

The strongest claim limitations are the combined use of HA, tretinoin, PEG, a multi-function antioxidant system, a chelator, substantial alcohol, and a minimum water level.

4-Hydroxyanisole

4-Hydroxyanisole is the principal stabilizing excipient identified in the claims. It is distinct from hydroquinone and should be analyzed under its chemical identity, concentration, and functional role.

A formulation containing tretinoin but no 4-hydroxyanisole would generally avoid the literal scope of claim 1. The doctrine of equivalents could raise a separate issue if a substitute performed substantially the same stabilizing function in substantially the same way, but the chemical specificity of the claims would make that analysis fact-dependent.

Tretinoin concentration

The broad claim covers 0.002% to 0.05% w/v tretinoin. That range includes common dermatological strengths such as 0.01%, 0.025%, and 0.05%.

The claim does not cover every tretinoin dosage form. Creams, gels, microsphere products, lotions, and aqueous suspensions may avoid the patent if they do not satisfy the claimed solution and excipient limitations.

PEG

Claim 1 requires a liquid low-molecular-weight polyethylene glycol. Claim 11 narrows this to PEG-8. The PEG limitation creates a meaningful distinction from formulations using carbomer, cellulose polymers, microspheres, liposomes, or other rheology modifiers.

Antioxidants and chelators

The antioxidant limitation is both compositional and functional. Claim 4 lists BHA, BHT, ascorbic acid, ascorbyl palmitate, lecithin, norhydroguaiaretic acid, propyl gallate, alpha-tocopherol, sodium bisulfite, cysteine, sodium metabisulfite, thioglycerol, thioglycolic acid, and thiomersal.

Claim 5 lists citric acid, disodium EDTA, phosphoric acid, tartaric acid, sorbitol, phenylalanine, and mixtures.

A formulation using a different antioxidant and a different chelator may avoid the narrower dependent claims while still requiring analysis under claim 1.

Water and pH

The minimum water content is a central distinction. Claim 1 requires at least 12% v/v water, while claims 6 and 7 increase the threshold to 15% and 20%.

The pH range is also material. The broad range is about 2.5 to 5. Claim 9 narrows the target to about pH 4. A formulation outside the claimed pH range may avoid literal infringement even if its excipient profile is otherwise similar.

When did US Patent 6,353,029 lose exclusivity?

US 6,353,029 issued on March 5, 2002. Under the modern US patent-term framework, utility patents generally expire 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory adjustments [1][2].

The patent is now expired and does not provide current enforceable exclusionary rights. The patent’s expiration means:

No current patent injunction should be based solely on US 6,353,029.
Generic manufacturers are not required to design around its claims for current US market entry.
The claims remain relevant as prior art against later formulation patents.
Historical licensing or settlement terms would not revive the expired patent.

The patent record, rather than the issue date alone, controls the precise expiration calculation. Patent-term adjustment and any related prosecution history should be checked in the USPTO Patent Center record for final diligence [2].

What is the Orange Book status of US 6,353,029?

US 6,353,029 is a formulation patent, but the patent number alone does not establish that it was listed in the FDA Orange Book.

Orange Book listing is tied to an approved drug application and the patent-listing certifications submitted by the NDA holder. FDA listing generally concerns patents claiming the drug substance, drug product, or an approved method of use, subject to the statutory listing requirements under the Hatch-Waxman framework [3][4].

For tretinoin products, Orange Book analysis must be performed at the product level, including the relevant NDA, dosage form, strength, and applicant. Products historically associated with tretinoin include Retin-A, Retin-A Micro, Renova, and other branded or generic topical products. A patent may be technically relevant to a formulation without being listed against every tretinoin NDA.

Because US 6,353,029 is expired, any former Orange Book listing would no longer create a live barrier to an abbreviated new drug application. The patent therefore has no current Paragraph IV blocking effect.

Are there Paragraph IV challenges to US 6,353,029?

No current Paragraph IV challenge can create meaningful market exclusivity around an expired patent. A Paragraph IV certification is relevant only when an ANDA applicant addresses an unexpired listed patent.

For a live tretinoin product patent, an ANDA applicant may certify that:

The patent has expired;
The applicant will wait until patent expiration;
The patent is invalid or unenforceable; or
The proposed product will not infringe.

For US 6,353,029, the practical certification position is expiration. A Paragraph IV strategy directed solely to this patent would have no present commercial value because the patent no longer supports delayed generic entry.

What patent landscape surrounds topical tretinoin?

The topical tretinoin landscape has historically divided into five patent categories:

Patent category	Typical protected subject matter	Relevance to US 6,353,029
Active ingredient patents	Tretinoin or retinoid compounds	Separate from the formulation claims
Stabilized solutions	Antioxidants, chelators, alcohol, PEG, water, pH	Directly overlapping technical field
Creams and gels	Emulsions, gel networks, solvents, penetration systems	Usually outside the claimed solution architecture
Microsphere systems	Encapsulated or controlled-release tretinoin	Separate delivery technology
Method-of-use patents	Acne, photoaging, hyperpigmentation, and dosing regimens	Potentially separate from formulation rights

The most relevant competitive products include:

Conventional tretinoin creams and gels;
Tretinoin microsphere gels;
Tretinoin lotions;
Tretinoin and clindamycin combinations;
Tretinoin formulations for acne;
Tretinoin formulations for facial photoaging.

Products using microspheres, polymeric gels, emulsions, or lotions may avoid the specific combination of liquid PEG, lower alkanol, high water content, and antioxidant/chelator system recited in US 6,353,029.

How does this patent compare with formulation patents for other tretinoin products?

US 6,353,029 is strongest against a conventional alcoholic solution resembling the disclosed formulation. It is less relevant to products whose stability or delivery depends on a different physical system.

Product architecture	Likely relationship to US 6,353,029
Alcoholic tretinoin solution with PEG-8 and HA	Highest technical overlap
Hydroalcoholic solution without HA	Lower literal overlap
Carbomer tretinoin gel	Generally outside the claimed solution architecture
Microsphere gel	Generally outside the claimed non-encapsulated solution
Oil-in-water cream	Generally outside the claimed alcoholic solution
Lotion with different stabilizers	Requires element-by-element analysis
Combination product with antibiotic	May implicate separate product and method claims

The patent does not claim therapeutic efficacy, acne treatment, photoaging treatment, or a specific dosing regimen in the supplied claims. Its scope is formulation-based.

Which companies could have commercial exposure?

Historical commercial exposure would have centered on companies marketing alcoholic tretinoin solutions or products using the disclosed stabilizer system. Relevant commercial entities in the broader tretinoin market have included Johnson & Johnson, Ortho Dermatologics, Valeant Pharmaceuticals, Bausch Health, Almirall, Mylan, Perrigo, Taro, Fougera, and other generic dermatology manufacturers.

Current revenue exposure from US 6,353,029 is zero as a matter of patent exclusivity because the patent has expired. Commercial exposure may still arise from:

Trade-secret manufacturing processes;
Separate active patents;
Regulatory exclusivity;
Trademark rights;
Product-specific formulation patents;
Process patents;
Contract manufacturing restrictions; and
State or federal market approvals.

Those rights must be analyzed independently. They do not extend the term of US 6,353,029.

What manufacturing and intellectual-property barriers remain?

The expired patent does not eliminate practical manufacturing barriers. Tretinoin is light-sensitive and oxidation-sensitive. Commercial manufacturers may still need validated controls for:

Oxygen exposure;
Light exposure;
Raw-material purity;
Antioxidant assay;
Chelator concentration;
pH control;
Water activity;
Container-closure compatibility;
Extractables and leachables;
Preservative performance; and
Long-term and accelerated stability.

These requirements affect FDA approval and manufacturing cost but are not equivalent to patent exclusivity. A generic manufacturer may use the disclosed formulation after patent expiration, subject to regulatory requirements and separate third-party rights.

What litigation and settlement issues affect the patent?

US 6,353,029 should not be treated as an active litigation asset. Any historical infringement case, Paragraph IV dispute, license, or settlement involving the patent would need to be evaluated by its date and contractual terms.

An expired patent can remain relevant in litigation involving:

Damages accrued before expiration;
Contractual royalty obligations;
Patent-license interpretation;
Patent misuse or antitrust claims;
Prior-art validity disputes; and
Continuation or divisional patents with separate terms.

The supplied claim set does not identify any continuation, divisional, reissue, or foreign counterpart. Those related rights cannot be inferred from the claims alone. The USPTO continuity data and assignment records control the analysis [2].

How strong is the patent estate for US 6,353,029?

The issued claims were commercially focused but technically narrow.

Strengths

Claim 1 combines multiple formulation elements.
The claims cover common tretinoin concentrations.
The antioxidant-function language addresses the stabilization mechanism.
Claim 13 provides a highly specific commercial embodiment.
The claims cover both broad and narrow water and pH ranges.

Weaknesses

The patent is expired.
The claims are limited to a solution, not all topical tretinoin products.
The claim requires a specific excipient combination.
Functional antioxidant limitations may create claim-construction and proof issues.
Alternative delivery systems can avoid substantial portions of the claim structure.
The use of broad terms such as "about" can create boundary disputes.

The estate therefore had meaningful historical blocking value for matching alcoholic solutions, but it was never a universal patent covering topical tretinoin.

What generic launch scenarios exist?

A generic manufacturer could pursue several design paths:

Match the disclosed formulation after patent expiration.
Use a different antioxidant system.
Remove PEG or substitute a different solvent system.
Use a gel, lotion, cream, or microsphere delivery system.
Use a different pH or water content.
Develop a different package and stability strategy.

The lowest technical-risk route after expiration may be a formulation close to claim 13, because the patent no longer imposes an exclusionary barrier. The principal remaining risks would be FDA approval, product quality, labeling, bioequivalence or therapeutic equivalence, manufacturing validation, and any separate live patent rights.

Key Takeaways

US 6,353,029 covers stabilized topical tretinoin solutions, not all topical tretinoin products.
Claim 1 requires HA, tretinoin, liquid low-molecular-weight PEG, a multi-function antioxidant system, a chelator, lower alkanol, water, and acidic pH.
Claim 13 recites a specific formulation using 2% HA, 0.01% tretinoin, ethanol, PEG-8, BHT, ascorbic acid, ascorbyl palmitate, citric acid, EDTA, and water.
The patent is expired and has no current blocking effect on generic US entry.
Any Orange Book relevance is product-specific and cannot be established from the patent number alone.
Paragraph IV challenges directed solely to this patent have no current exclusionary significance.
The patent remains important as formulation prior art and as a technical reference for tretinoin stability.
Separate live patents, regulatory protections, trade secrets, and manufacturing rights must be analyzed independently.

FAQs

Does US 6,353,029 cover tretinoin cream?

No. The claims are directed to a topical solution with a specified alcoholic, PEG-containing, antioxidant, chelator, water, and pH system. A conventional tretinoin cream would not ordinarily satisfy those limitations.

Can a generic manufacturer use the claim 13 formulation?

Yes, the patent’s expiration removes its patent-based restriction. The manufacturer must still satisfy FDA approval, quality, labeling, and applicable requirements under the ANDA or other relevant regulatory pathway.

Is 4-hydroxyanisole the same as hydroquinone?

No. 4-Hydroxyanisole is also known as 4-methoxyphenol. It is chemically distinct from hydroquinone and should not be treated as interchangeable for claim analysis.

Does a formulation with 0.01% tretinoin automatically infringe?

No. Tretinoin concentration is only one claim limitation. The product would also need to satisfy the solution, HA, PEG, antioxidant, chelator, alcohol, water, pH, and functional antioxidant requirements.

Can an expired formulation patent still affect a new tretinoin product?

Yes, as prior art and as a technical disclosure. It cannot generally provide current exclusionary rights, but it may affect the validity of later patents claiming similar stabilization systems.

References

United States Patent and Trademark Office. (2024). Patent term calculator. U.S. Department of Commerce. https://www.uspto.gov/learning-and-resources/patent-and-trademark-practitioners/resources/patent-term-calculator
United States Patent and Trademark Office. (2024). Patent Center. U.S. Department of Commerce. https://patentcenter.uspto.gov/
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
U.S. Food and Drug Administration. (2024). Small business assistance: Frequently asked questions on the patent certification requirements and the 30-month stay. https://www.fda.gov/drugs/development-resources/patent-certification-requirements-and-30-month-stay
U.S. Patent No. 6,353,029. (2002). Stable topical tretinoin compositions. United States Patent and Trademark Office.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	8100301	⤷ Start Trial
Brazil	0113460	⤷ Start Trial
Canada	2419877	⤷ Start Trial
China	1225247	⤷ Start Trial
China	1447681	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,353,029

Summary for Patent: 6,353,029